What is Xvivo Perfusion AB (publ) (XVIPF)?

Xvivo Perfusion AB (publ) (XVIPF) is a stock in the Healthcare sector, Medical - Devices industry. View full analysis on Stocks360.

What is the current price of XVIPF?

The current price of XVIPF is $21.68. Prices are updated in real time on Stocks360.

What is XVIPF's price-to-earnings (PE) ratio?

XVIPF's trailing twelve-month PE ratio is 49.93, based on current price and earnings per share data available on Stocks360.

What is XVIPF's market capitalization?

XVIPF's market capitalization is $682,908,510.00, placing it in the small-cap tier.

Xvivo Perfusion AB (publ) (XVIPF)

Stock analysis · OTC · Healthcare · Medical - Devices

$21.68

Market Cap

$682.91M

PE (TTM)

49.93

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

1.46

Day Range

$21.68 – $21.80

52-wk Range

$16.98 – $30.95

Avg Volume

N/A

Volume

592.00

Xvivo Perfusion AB (publ) (XVIPF) is a publicly traded company in the Healthcare sector. Latest price: $21.68. Market cap $682.91M. Trailing PE 49.93. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

You have viewed 14 SEO analysis pages

Unlock saved watchlists, personalized setups, and referral credits with a free Stocks360 account.

Continue with free signup

1-Year Price

2025-10-30 · $16.98 2026-10-27 · $21.68 (+27.68%)

Earnings

Most Recent

Oct 22, 2026

EPS $0.14 vs est. $0.06

Beat by $0.08

Next Earnings

Jan 28, 2027

EPS estimate $0.09

Proprietary Signals

Signal snapshot temporarily unavailable.

About Xvivo Perfusion AB (publ)

Xvivo Perfusion AB (publ) is a medical technology company dedicated to advancing transplantation medicine. The firm specializes in pioneering solutions for the preservation and perfusion of organs, tissues, and cells, essential for successful transplant procedures. With a significant international presence, Xvivo Perfusion operates across diverse markets, including Sweden, the United States, wider North and South America, Europe, the Middle East, Africa, and the Asia Pacific region. Among its key product offerings is the XVIVO System (XPS), an integrated, ready-to-use cardiac bypass apparatus designed for normothermic ex vivo lung perfusion (EVLP). Complementing this, the company provides the XPS Disposable Lung Kit, comprising sterile, pre-packaged components required for EVLP, and STEEN Solution, a specialized buffered extracellular fluid used for perfusing isolated donor lungs during the EVLP process. Xvivo also offers Perfadex Plus, an extracellular, low-potassium, dextran-based electrolyte solution crucial for preservation. Other significant products include the XVIVO Silicone Tubing Set for rapid flushing of donor lungs post-procurement; the XVIVO LS and XVIVO Disposable Lun…

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	49.93×
P/S (TTM)	6.71×
P/B	2.84×
PEG	0.15×
P/FCF (TTM)	33.58×
EV / EBITDA	30.71×
EV / Sales	6.51×
Earnings Yield	2.00%
Free Cash Flow Yield	2.98%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$6.24B
Revenue (TTM)	$958.65M
Net Income (TTM)	$128.85M
Free Cash Flow (TTM)	$246.84M
Net Debt	-$192.63M
Working Capital	$542.20M
Gross Margin	61.82%
Operating Margin	12.58%
Net Margin	13.44%
Return on Equity	5.89%
Return on Invested Capital	4.14%